Protagenic Therapeutics, Inc.(PTIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PTIX Protagenic Therapeutics, Inc.

Trading 03-25 11:52:20 EDT Delay

{"stockData":{"symbol":"PTIX","market":"US","secType":"STK","nameCN":"Protagenic Therapeutics, Inc.","latestPrice":0.7,"timestamp":1774453940531,"preClose":0.7,"halted":0,"volume":12851,"delay":15,"changeRate":0,"floatShares":1914900,"shares":1934878,"eps":-5.303,"marketStatus":"Trading","change":0,"latestTime":"03-25 11:52:20 EDT Delay","open":0.72,"high":0.7647,"low":0.6,"amount":7958.772700000001,"amplitude":0.235286,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-5.303,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774468800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.7,"volumeRatio":4.802598},"requestUrl":"/m/hq/s/PTIX/tweets","defaultTab":"tweets","newsList":[{"id":"2620421239","title":"Protagenic Therapeutics completes Phytanix separation and removes USD 6.3 million in liabilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2620421239","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620421239?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:00","pubTimestamp":1773748852,"startTime":"0","endTime":"0","summary":"Protagenic said it completed a settlement and separation related to its prior Phytanix Bio acquisition, simplifying its capital structure and narrowing operational focus to PT00114. The company said 117,690 common shares issued in the May 2025 transaction were returned and cancelled, leaving 1,810,208 common shares outstanding. Protagenic said the separation removed more than 6.3 million in liabilities, reducing total liabilities to about 0.5 million. It also said the separation eliminated more than 1 million in annualized costs by terminating Phytanix-related employment, consulting and advisory arrangements.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDLtm5Kb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTIX"],"gpt_icon":0},{"id":"2618623176","title":"Protagenic Therapeutics Q3 FY2026 operating loss rises 130% to USD 0.93 million on revenue of USD 0.75 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618623176","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618623176?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:47","pubTimestamp":1773056824,"startTime":"0","endTime":"0","summary":"Protagenic reported a loss from operations of USD 0.93 million for Q3 ended Dec. 31, 2025, widening 130% from a year earlier. Legal fees rose to USD 0.22 million, up 565%, and general and administrative expenses increased to USD 0.15 million, up 212%. For the nine months ended Dec. 31, 2025, loss from operations was USD 4.38 million, up more than tripled, while research and development expense increased to USD 0.82 million, up 381%. Operating activities used USD 3.07 million in cash for the nine months, and cash was USD 2.21 million as of Dec. 31, 2025. The company said it expects its cash resources to fund operations until approximately the end of Q2 FY 2027 .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDLqbXBH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTIX"],"gpt_icon":0},{"id":"2616349467","title":"Protagenic Therapeutics Names William Nichols Jr. President","url":"https://stock-news.laohu8.com/highlight/detail?id=2616349467","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616349467?lang=en_us&edition=fundamental","pubTime":"2026-03-03 19:06","pubTimestamp":1772535967,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics Inc. appointed William  Nichols, Jr., 51, as President on February 3, 2026. Nichols previously held senior commercial leadership roles at bluebird bio and earlier at Dova Pharmaceuticals  and Bristol-Myers Squibb.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDLZc7cL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0321505868.SGD","BMY","IE00BJJMRZ35.SGD","LU0225771236.USD","LU0868494617.USD","LU1670710661.SGD","BK4534","IE00BFTCPJ56.SGD","BK4585","LU0096364046.USD","LU2242652126.USD","BK4139","BK4559","BK4581","LU0237698245.USD","IE00BJT1NW94.SGD","IE0009355771.USD","LU1868836591.USD","IE0002141913.USD","BK4532","LU2360032135.SGD","LU1291159041.SGD","LU0321505439.SGD","LU1883839398.USD","PTIX","LU1093756168.USD","LU1718418525.SGD","LU1868836757.USD","LU2133065610.SGD","LU2242646821.SGD","LU1261432733.SGD","LU1868837300.USD","IE00BFXG1179.USD","LU1074936037.SGD","LU1989771016.USD","LU2125154935.USD","LU2125154778.USD","LU1868837136.USD","LU1032466523.USD","LU0061475181.USD","LU1670710588.SGD","IE00B2B36J28.USD","LU1571399168.USD","LU0306807586.USD","LU0114720955.EUR","LU1670711123.USD","LU0456855351.SGD","LU1093756325.SGD","LU0985481810.HKD"],"gpt_icon":0},{"id":"2613904107","title":"Protagenic Therapeutics: on Feb 17, Co Enters Settlement Agreement With Former Phytanix Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2613904107","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613904107?lang=en_us&edition=fundamental","pubTime":"2026-02-24 19:07","pubTimestamp":1771931234,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK0NJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PTIX","ABTI"],"gpt_icon":0},{"id":"2613790469","title":"Protagenic Therapeutics Settles Delaware Chancery Litigation and Unwinds Phytanix Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2613790469","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613790469?lang=en_us&edition=fundamental","pubTime":"2026-02-24 19:04","pubTimestamp":1771931069,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics Inc. has entered into a settlement agreement to resolve a Delaware Court of Chancery lawsuit, Protagenic Therapeutics, Inc. v. Alterola Biotech Inc., et al. The settlement provides for dismissal of the case and unwinds the company’s May 2025 share exchange that had made it the owner of Phytanix Bio, with the former Phytanix stockholders returning PTIX shares and re-acquiring full ownership of Phytanix Bio. Protagenic also agreed to pay Phytanix Bio $300,000 at closing and an additional $10,000 after receiving specified financial information.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Ga","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL9G6xPt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABTI","PTIX","BK4139"],"gpt_icon":0},{"id":"2612410477","title":"Protagenic Therapeutics Delays Quarterly 10-Q Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2612410477","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612410477?lang=en_us&edition=fundamental","pubTime":"2026-02-18 19:49","pubTimestamp":1771415358,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics Inc. filed a Form 12b-25 late-filing notice stating it will not be able to file its quarterly report on Form 10Q for the period ended Dec. 31, 2025 by the prescribed due date without unreasonable effort or expense. The company said it does not expect to file the Form 10Q within the five-day extension period allowed under SEC Rule 12b25.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL3Ld70w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTIX","BK4139"],"gpt_icon":0},{"id":"2601988995","title":"Protagenic Therapeutics Faces Nasdaq Delisting Over Listing Rule Violations","url":"https://stock-news.laohu8.com/highlight/detail?id=2601988995","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601988995?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:45","pubTimestamp":1767617157,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics Inc. is facing regulatory challenges after receiving notice from Nasdaq regarding its failure to meet continued listing requirements, specifically the minimum stockholders' equity and timely filing of periodic reports. As a result, the company's securities are set to be delisted from Nasdaq, with trading expected to move to the over-the-counter  market beginning January 5, 2026. The company is evaluating steps to regain compliance with Nasdaq listing standards and is considering seeking relisting on a national securities exchange. There are currently no mentions of tariffs impacting the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to gen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL3jchjs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTIX","BK4139"],"gpt_icon":0},{"id":"2590134146","title":"Protagenic Therapeutics Reports Positive Phase 1 Results for PT00114 in Stress-Related Psychiatric Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2590134146","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590134146?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:46","pubTimestamp":1765287984,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics Inc. has announced positive topline safety results from its Phase 1 Multiple Dose study of PT00114, a synthetic analogue of a naturally occurring brain peptide aimed at treating stress-related neuropsychiatric conditions. The Phase 1 study, conducted in healthy volunteers, evaluated the safety, tolerability, and pharmacokinetic profile of PT00114 across multiple dose levels. No serious adverse events were observed, and reported adverse events were consistent with expectations for a peptide-based injectable therapy, including expected injection-site reactions. All participants completed the assigned dosing schedules. Protagenic Therapeutics is finalizing a comprehensive analysis of the Phase 1 dataset and plans to initiate a Phase 2 study in early 2026 to further evaluate PT00114 in patients with chronic stress-related psychiatric disorders. Detailed results and study design information for the next phase will be communicated in the coming months.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL8V71nz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTIX","BK4139"],"gpt_icon":0},{"id":"2589081008","title":"Protagenic Therapeutics Inc. Announces Date for Upcoming Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2589081008","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589081008?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:53","pubTimestamp":1764971620,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics Inc. has announced that it will hold its annual meeting of stockholders on December 31, 2025. The meeting will be conducted as a virtual event via live webcast.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL79jJWV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTIX","BK4139"],"gpt_icon":0},{"id":"2586181738","title":"Sector Update: Health Care Stocks Mixed Premarket Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2586181738","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586181738?lang=en_us&edition=fundamental","pubTime":"2025-11-28 22:20","pubTimestamp":1764339612,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed premarket Friday, with the Health Care Select Sector SPDR Fund (XLV) slightly lower and the iShares Biotechnology ETF (IBB) up 0.3%.Biogen (BIIB) and Eisai said a new dru","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B19Z9Z06.USD","LU0109394709.USD","BK4588","LU0320765992.SGD","LU0234570918.USD","IE00B894F039.SGD","XLV","IE00B19Z9P08.USD","BK4585","BK4581","IBB","XBI","BK4139","BK4533","VNDA","LU0889565916.HKD","BK4532","PTIX","BIIB","LABU"],"gpt_icon":0},{"id":"2586202036","title":"Protagenic Therapeutics Faces Nasdaq Delisting Due to Compliance Issues","url":"https://stock-news.laohu8.com/highlight/detail?id=2586202036","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586202036?lang=en_us&edition=fundamental","pubTime":"2025-11-28 16:46","pubTimestamp":1764319560,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics  said Thursday it received a Nasdaq notice for failing to meet the minimum $2.5 million stockholders' equity requirement and for not filing its quarterly report on time.The company said Nasdaq flagged its recently reported equity levels and the delayed Form 10-Q for the quarter ended Sept. 30, 2025. Because the company had only recently regained compliance and remains under a mandatory panel monitoring period, Nasdaq has moved to delist its shares.The company said it will request a hearing, which automatically halts any suspension for 15 days, and will also seek an additional stay while the panel reviews its case.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PSQ","BK4007","MNQmain","NVIW.SI","QLD","USAW.SI","LENZ","BK4139","PTIX","SQQQ","TSYW.SI","QID","TQQQ",".IXIC","NQmain","USJW.SI","BK4539"],"gpt_icon":1},{"id":"2586260216","title":"Protagenic Therapeutics Delays Quarterly Financial Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2586260216","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586260216?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:19","pubTimestamp":1764191977,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics Inc. has disclosed a delay in filing its Form 10-Q for the quarter ended September 30, 2025. This reporting delay was cited as one of the reasons the company received a Nasdaq non-compliance notice.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDLbYgXt5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTIX","BK4139"],"gpt_icon":0},{"id":"2583000682","title":"Protagenic Therapeutics Delays Quarterly Report Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583000682","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583000682?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:05","pubTimestamp":1763157927,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics Inc. has disclosed a delay in filing its Quarterly Report on Form 10-Q for the period ended September 30, 2025. The company cited that it could not file the report by the prescribed due date without unreasonable effort or expense and expects to file within the five-day extension permitted by SEC rules.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 14, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL9t2BV7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTIX"],"gpt_icon":0},{"id":"2583598723","title":"Protagenic Therapeutics Completes Dosing in Phase 1 Study of Lead Compound PT00114","url":"https://stock-news.laohu8.com/highlight/detail?id=2583598723","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583598723?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:22","pubTimestamp":1763040140,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics Inc. announced the completion of enrollment and dosing in its Phase 1 Multiple Ascending Dose  study of PT00114, a peptide-based therapeutic for stress-related neuropsychiatric and neurodegenerative disorders. The study was conducted in healthy volunteers to assess the safety and tolerability of PT00114 following multiple doses. The company previously completed a single ascending dose study earlier in 2025. Protagenic Therapeutics stated that top-line results from the MAD study are expected to be finalized and released by November 30th, and a full analysis of the safety results will be presented by the end of the month.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the ori","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL5MTWcr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTIX","BK4139"],"gpt_icon":0},{"id":"2581161702","title":"Jennifer Chao Resigns from Protagenic Therapeutics Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2581161702","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581161702?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:27","pubTimestamp":1762378048,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics Inc. announced that Jennifer Chao has resigned from its Board of Directors, effective immediately. The company stated there were no disagreements between Ms. Chao and the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDLwx2N8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTIX"],"gpt_icon":0},{"id":"2580115504","title":"Protagenic Therapeutics Inc: Files Complaint to Rescind Share Exchange Agreement by Which Co Acquired Phytanix Bio - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2580115504","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580115504?lang=en_us&edition=fundamental","pubTime":"2025-11-01 05:19","pubTimestamp":1761945549,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nFWN3WC34I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PTIX"],"gpt_icon":0},{"id":"2578523226","title":"Protagenic Therapeutics: May Offer and Sell Shares of Common Stock of up to $1.75 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2578523226","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578523226?lang=en_us&edition=fundamental","pubTime":"2025-10-25 05:42","pubTimestamp":1761342170,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nFWN3W52LV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTIX","BK4139"],"gpt_icon":0},{"id":"2578154132","title":"Protagenic Therapeutics Files Initial Beneficial Ownership Statement; Ex-CEO and Director Barrett Evans Named as 10% Owner","url":"https://stock-news.laohu8.com/highlight/detail?id=2578154132","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578154132?lang=en_us&edition=fundamental","pubTime":"2025-10-25 01:41","pubTimestamp":1761327672,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing names Barrett Evans as the beneficial owner, who serves as a Director, 10% Owner, and former CEO of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 24, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL7dvxct:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTIX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.protagenic.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.3333},{"period":"3month","weight":0.3333},{"period":"6month","weight":0},{"period":"1year","weight":0.005},{"period":"ytd","weight":0}],"description":"Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.","exchange":"OTCQB","name":"Protagenic Therapeutics, Inc.","nameEN":"Protagenic Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Protagenic Therapeutics, Inc.(PTIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Protagenic Therapeutics, Inc.(PTIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Protagenic Therapeutics, Inc.,PTIX,Protagenic Therapeutics, Inc.股票,Protagenic Therapeutics, Inc.股票老虎,Protagenic Therapeutics, Inc.股票老虎国际,Protagenic Therapeutics, Inc.行情,Protagenic Therapeutics, Inc.股票行情,Protagenic Therapeutics, Inc.股价,Protagenic Therapeutics, Inc.股市,Protagenic Therapeutics, Inc.股票价格,Protagenic Therapeutics, Inc.股票交易,Protagenic Therapeutics, Inc.股票购买,Protagenic Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Protagenic Therapeutics, Inc.(PTIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Protagenic Therapeutics, Inc.(PTIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction